Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach

Brian Godman, Mohammed Abuelkhair, Agnes Vitry, Shajahan Abdu, Marion Bennie, Iain Bishop, Harald Herholz, Andrew Martin, Catherine Sermet

Research output: Contribution to journalArticle

Abstract

Pharmaceutical expenditure continues to rise driven by a number of factors including ageing populations and the continued launch of new premium-priced drugs. Increasing use of generics versus originators and patent-protected products of the same or related classes can help conserve valuable resources. However, concerns with their effectiveness and safety compared to originators as well as only limited introduction of measures to promote their demand in some countries have led to variable use among countries. Countries need to learn from each other to further enhance their prescribing efficiency. Firstly to review successful case histories from different countries, and secondly, raise awareness about potential pitfalls that could undermine the success of future measures in order to provide future guidance on conserving resources in relation to generics. A narrative review of case histories selected by co-authors using a range of different approaches. Systematic reviews are published elsewhere. Twelve case histories were selected depicting both supply- and demand-side measures. These include Croatia where the introduction of additional measures helped reduce drug expenditure as well as debt whilst improving access to new medicines, Lithuania where recent reforms decreased pharmaceutical expenditure in 2010 whilst the number of prescriptions increased by 9% versus 2009; Scotland where despite a 6.2 fold increase in statin utilisation, multiple measures limited the increase in reimbursed expenditure to just 7% in 2010 vs 2001; Sweden where the introduction of monthly auctions for generics has helped lower prices; and the US where managed care organisations actively encourage cross therapeutic opportunities for generics substitution where the safety and efficacy of a generic drug is similar to a patent-protected product in the class or related class to conserve resources. Payers across Australia, Europe, Middle East (United Arab Emirates), and US have introduced multiple measures to both enhance the prescribing of generics and obtain lower prices, with the result that they are increasingly able to take advantage of the availability of generics. However, due to growing pressures on healthcare resources, it is important that countries accelerate the sharing of lessons learned about which policies and new measures are most effective in controlling costs.
LanguageEnglish
Pages69-83
Number of pages15
JournalGenerics and Biosimilars Initiative journal
Volume1
Issue number2
Early online date6 May 2012
DOIs
Publication statusPublished - 2012

Fingerprint

Health Expenditures
Pharmaceutical Preparations
Drug Substitution
United Arab Emirates
Lithuania
Generic Drugs
Safety
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Croatia
Middle East
Managed Care Programs
Scotland
Sweden
Medicine
Prescriptions
Substitution reactions
Aging of materials
Availability
Organizations
Delivery of Health Care

Keywords

  • generics
  • demand-side measures
  • pharmaceuticals
  • pharmaceutical pricing

Cite this

Godman, Brian ; Abuelkhair, Mohammed ; Vitry, Agnes ; Abdu, Shajahan ; Bennie, Marion ; Bishop, Iain ; Herholz, Harald ; Martin, Andrew ; Sermet, Catherine. / Payers endorse generics to enhance prescribing efficiency : impact and future implications, a case history approach. In: Generics and Biosimilars Initiative journal. 2012 ; Vol. 1, No. 2. pp. 69-83.
@article{51f2e5cf16564724b8a613d273cb73bf,
title = "Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach",
abstract = "Pharmaceutical expenditure continues to rise driven by a number of factors including ageing populations and the continued launch of new premium-priced drugs. Increasing use of generics versus originators and patent-protected products of the same or related classes can help conserve valuable resources. However, concerns with their effectiveness and safety compared to originators as well as only limited introduction of measures to promote their demand in some countries have led to variable use among countries. Countries need to learn from each other to further enhance their prescribing efficiency. Firstly to review successful case histories from different countries, and secondly, raise awareness about potential pitfalls that could undermine the success of future measures in order to provide future guidance on conserving resources in relation to generics. A narrative review of case histories selected by co-authors using a range of different approaches. Systematic reviews are published elsewhere. Twelve case histories were selected depicting both supply- and demand-side measures. These include Croatia where the introduction of additional measures helped reduce drug expenditure as well as debt whilst improving access to new medicines, Lithuania where recent reforms decreased pharmaceutical expenditure in 2010 whilst the number of prescriptions increased by 9{\%} versus 2009; Scotland where despite a 6.2 fold increase in statin utilisation, multiple measures limited the increase in reimbursed expenditure to just 7{\%} in 2010 vs 2001; Sweden where the introduction of monthly auctions for generics has helped lower prices; and the US where managed care organisations actively encourage cross therapeutic opportunities for generics substitution where the safety and efficacy of a generic drug is similar to a patent-protected product in the class or related class to conserve resources. Payers across Australia, Europe, Middle East (United Arab Emirates), and US have introduced multiple measures to both enhance the prescribing of generics and obtain lower prices, with the result that they are increasingly able to take advantage of the availability of generics. However, due to growing pressures on healthcare resources, it is important that countries accelerate the sharing of lessons learned about which policies and new measures are most effective in controlling costs.",
keywords = "generics , demand-side measures , pharmaceuticals, pharmaceutical pricing",
author = "Brian Godman and Mohammed Abuelkhair and Agnes Vitry and Shajahan Abdu and Marion Bennie and Iain Bishop and Harald Herholz and Andrew Martin and Catherine Sermet",
note = "Strathprints' policy is to record up to 8 authors per publication, plus any additional authors based at the University of Strathclyde. More authors may be listed on the official publication than appear in the Strathprints' record.",
year = "2012",
doi = "10.5639/gabij.2012.0102.017",
language = "English",
volume = "1",
pages = "69--83",
journal = "Generics and Biosimilars Initiative journal",
issn = "2033-6403",
number = "2",

}

Payers endorse generics to enhance prescribing efficiency : impact and future implications, a case history approach. / Godman, Brian; Abuelkhair, Mohammed ; Vitry, Agnes ; Abdu, Shajahan; Bennie, Marion; Bishop, Iain ; Herholz, Harald; Martin, Andrew; Sermet, Catherine.

In: Generics and Biosimilars Initiative journal, Vol. 1, No. 2, 2012, p. 69-83.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Payers endorse generics to enhance prescribing efficiency

T2 - Generics and Biosimilars Initiative journal

AU - Godman, Brian

AU - Abuelkhair, Mohammed

AU - Vitry, Agnes

AU - Abdu, Shajahan

AU - Bennie, Marion

AU - Bishop, Iain

AU - Herholz, Harald

AU - Martin, Andrew

AU - Sermet, Catherine

N1 - Strathprints' policy is to record up to 8 authors per publication, plus any additional authors based at the University of Strathclyde. More authors may be listed on the official publication than appear in the Strathprints' record.

PY - 2012

Y1 - 2012

N2 - Pharmaceutical expenditure continues to rise driven by a number of factors including ageing populations and the continued launch of new premium-priced drugs. Increasing use of generics versus originators and patent-protected products of the same or related classes can help conserve valuable resources. However, concerns with their effectiveness and safety compared to originators as well as only limited introduction of measures to promote their demand in some countries have led to variable use among countries. Countries need to learn from each other to further enhance their prescribing efficiency. Firstly to review successful case histories from different countries, and secondly, raise awareness about potential pitfalls that could undermine the success of future measures in order to provide future guidance on conserving resources in relation to generics. A narrative review of case histories selected by co-authors using a range of different approaches. Systematic reviews are published elsewhere. Twelve case histories were selected depicting both supply- and demand-side measures. These include Croatia where the introduction of additional measures helped reduce drug expenditure as well as debt whilst improving access to new medicines, Lithuania where recent reforms decreased pharmaceutical expenditure in 2010 whilst the number of prescriptions increased by 9% versus 2009; Scotland where despite a 6.2 fold increase in statin utilisation, multiple measures limited the increase in reimbursed expenditure to just 7% in 2010 vs 2001; Sweden where the introduction of monthly auctions for generics has helped lower prices; and the US where managed care organisations actively encourage cross therapeutic opportunities for generics substitution where the safety and efficacy of a generic drug is similar to a patent-protected product in the class or related class to conserve resources. Payers across Australia, Europe, Middle East (United Arab Emirates), and US have introduced multiple measures to both enhance the prescribing of generics and obtain lower prices, with the result that they are increasingly able to take advantage of the availability of generics. However, due to growing pressures on healthcare resources, it is important that countries accelerate the sharing of lessons learned about which policies and new measures are most effective in controlling costs.

AB - Pharmaceutical expenditure continues to rise driven by a number of factors including ageing populations and the continued launch of new premium-priced drugs. Increasing use of generics versus originators and patent-protected products of the same or related classes can help conserve valuable resources. However, concerns with their effectiveness and safety compared to originators as well as only limited introduction of measures to promote their demand in some countries have led to variable use among countries. Countries need to learn from each other to further enhance their prescribing efficiency. Firstly to review successful case histories from different countries, and secondly, raise awareness about potential pitfalls that could undermine the success of future measures in order to provide future guidance on conserving resources in relation to generics. A narrative review of case histories selected by co-authors using a range of different approaches. Systematic reviews are published elsewhere. Twelve case histories were selected depicting both supply- and demand-side measures. These include Croatia where the introduction of additional measures helped reduce drug expenditure as well as debt whilst improving access to new medicines, Lithuania where recent reforms decreased pharmaceutical expenditure in 2010 whilst the number of prescriptions increased by 9% versus 2009; Scotland where despite a 6.2 fold increase in statin utilisation, multiple measures limited the increase in reimbursed expenditure to just 7% in 2010 vs 2001; Sweden where the introduction of monthly auctions for generics has helped lower prices; and the US where managed care organisations actively encourage cross therapeutic opportunities for generics substitution where the safety and efficacy of a generic drug is similar to a patent-protected product in the class or related class to conserve resources. Payers across Australia, Europe, Middle East (United Arab Emirates), and US have introduced multiple measures to both enhance the prescribing of generics and obtain lower prices, with the result that they are increasingly able to take advantage of the availability of generics. However, due to growing pressures on healthcare resources, it is important that countries accelerate the sharing of lessons learned about which policies and new measures are most effective in controlling costs.

KW - generics

KW - demand-side measures

KW - pharmaceuticals

KW - pharmaceutical pricing

U2 - 10.5639/gabij.2012.0102.017

DO - 10.5639/gabij.2012.0102.017

M3 - Article

VL - 1

SP - 69

EP - 83

JO - Generics and Biosimilars Initiative journal

JF - Generics and Biosimilars Initiative journal

SN - 2033-6403

IS - 2

ER -